Skip to main content
XRAY
NASDAQ Industrial Applications And Services

Dentsply Sirona 10-Q: Q3 Loss, $75M Securities Settlement, Zero Free Cash Flow

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$8.72
Mkt Cap
$2.011B
52W Low
$8.32
52W High
$14.755
52W Position info
4.8% above low
Off High info
41% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

XRAY is trading near its 52-week low of $8.32 (4.8% above the low).

Summary

Dentsply Sirona's Q3 10-Q shows $836 million in sales and a $0.01 loss per share, plus a $75 million insured settlement of the 2024 securities suit and zero free cash flow for the quarter.


Key Events · Earnings and Guidance · XRAY

  • Q3 Sales Fall 7.6%

    Net sales were $836 million versus $904 million a year ago, with a GAAP diluted loss of $0.01 per share against a $2.14 loss last year.

  • $75M Securities Settlement

    An October 20, 2026 MOU settles the 2024 securities litigation for $75 million, funded by D&O insurers with an offsetting receivable, so no P&L impact; court approval is still required.

  • Accounting Change Lifts Results

    A revised intercompany inventory profit-elimination method added about $30 million, or $0.15 per share, to net income for the quarter and nine months; the company says equivalent impacts are not expected in future periods.

  • Cash and Free Cash Flow Thin

    Cash fell to $195 million from $326 million at December 31, 2025; nine-month operating cash flow was $171 million and Q3 free cash flow was $0 million.


Analysis · XRAY · Industrial Applications And Services

The quarter was already public, but the 10-Q fills in what the 8-K did not. It discloses a $75 million settlement of the 2024 Byte-related securities class action, fully insured so there is no P&L hit, and a $30 million one-time boost from a change in inventory accounting that flattered the quarter. Meanwhile the balance sheet is thinning: cash fell to $195 million from $326 million at year-end while free cash flow was zero. With the stock near its 52-week low, a suspended dividend, leverage covenants loosened only through year-end 2026, and a trimmed outlook, the focus stays on cash generation rather than the headline loss.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XRAY was trading at $8.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $8.32 to $14.76. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XRAY - Latest Insights

XRAY
Nov 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.06
Real-time Price: $8.35 info
Change: -$1.71 (-17%) info
Market Cap: $1.682B info
XRAY
Oct 09, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.83
Real-time Price: $8.35 info
Change: -$0.480 (-5%) info
Market Cap: $1.682B info
XRAY
Aug 06, 2026, 4:56 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $13.07
Real-time Price: $8.35 info
Change: -$4.72 (-36%) info
Market Cap: $1.682B info
XRAY
Aug 06, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $13.50
Real-time Price: $8.35 info
Change: -$5.15 (-38%) info
Market Cap: $1.682B info
XRAY
Jul 01, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.09
Real-time Price: $8.35 info
Change: -$2.74 (-25%) info
Market Cap: $1.682B info